GSK•benzinga•
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Summary
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2024 by benzinga